Abstract
Phenytoin is an 80-year young molecule and new indications are still emerging. The neuroprotective potential of phenytoin has been evaluated for decades. Recently, a positive phase II trial supported its further development in the treatment of optic neuritis in multiple sclerosis. In 1942, however, peripheral neuritis was first reported to be an adverse event of phenytoin, and since then a small but steady stream of publications discussed peripheral polyneuropathy as being a possible adverse event of phenytoin. We have reviewed the literature and concluded there is some supportive evidence for a reversible polyneuropathy after the oral use of phenytoin, though with no evidence for clear neurotoxicity on the level of peripheral nerves. This is probably due to the fact that the pharmacological effects of phenytoin, based on the stabilizing effect of the voltage-gated sodium channels, make impairment of nerve conduction in asymptomatic and symptomatic reversible polyneuropathies plausible. Clear toxically-induced phenytoin-related polyneuropathies, however, are extremely rare and are always related to high dose or high plasma levels of phenytoin, mostly developing during many years of therapy. We could only find one case of a probable reversible chronic phenytoin intoxication resulting in a biopsy proven axonal atrophy with secondary demyelination and signs of remyelination. All case series and case reports published are insufficient in detail to prove a clear causal relation between phenytoin intake and the induction of a peripheral polyneuropathy. Phenytoin does not lead to irreversible toxicity of the peripheral nerves and might, on the other hand, have neuroprotective properties.
Similar content being viewed by others
References
Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259–269
Boxer PA, Cordon JJ, Mann ME, Rodolosi LC, Vartanian MG, Rock DM, Taylor CP, Marcoux FW (1990) Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in rat. Stroke 21(11 Suppl):III47–III51
Lakics V, Molnar P, Erdo SL (1995) Protection against veratridine toxicity in rat cortical cultures: relationship to sodium channel blockade. Neuroreport 7(1):89–92
Fern R, Ransom BR, Stys PK, Waxman SG (1993) Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J Pharmacol Exp Ther 266(3):1549–1555
Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90(5):3566–3571
Zeng Z, Hill-Yardin EL, Williams DA, O'Brien TJ, Serelis A, French CR (2016) The Effect of Phenytoin on Sodium Conductances in Rat Hippocampal CA1 Pyramidal Neurons. J Neurophysiol 3 (01060)
Finkelman I, Arieff AJ (1942) Untoward effects of phenytoin sodium in epilepsy. J Am Med Assoc 118(14):1209–1212. doi:10.1001/jama.1942.02830140039012
Toman JE (1949) The neuropharmacology of antiepileptics. Electroencephalogr Clin Neurophysiol 1(1):33–44
Morrell F, Bradley W, Ptashne M (1958) Effect of diphenylhydantoin on peripheral nerve. Neurology 8(2):140–144
Brumlik J, Moretti L (1966) The effect of diphenylhydantoin on nerve conduction velocity. Neurology 16(12):1217–1218
Lovelace RE, Horwitz SJ (1968) Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch Neurol 18(1):69–77
Birket-Smith E, Krogh E (1971) Motor nerve conduction velocity during diphenylhydantoin intoxication. Acta Neurol Scand 47(3):265–271
Eisen AA, Woods JF, Sherwin AL (1974) Peripheral nerve function in long-term therapy with diphenylhydantoin. A clinical and electrophysiologic correlation. Neurology 24(5):411–417
Encinoza O (1974) Nerve conduction velocity in patients on long-term diphenylhydantoin therapy. Epilepsia 15(2):147–154
Argov Z, Mastaglia FL (1979) Drug-induced peripheral neuropathies. Br Med J 1(6164):663–666
Reynolds EH (1973) Anticonvulsants, folic acid, and epilepsy. Lancet 1(7816):1376–1378
Martinez Figueroa A, Johnson RH, Lambie DG, Shakir RA (1980) The role of folate deficiency in the development of peripheral neuropathy caused by anticonvulsants. J Neurol Sci 48(3):315–323
Horwitz SJ, Klipstein FA, Lovelace RE (1968) Relation of abnormal folate metabolism to neuropathy developing during anticonvulsant drug therapy. Lancet 1(7542):563–565
Mochizuki Y, Suyehiro Y, Tanizawa A, Ohkubo H, Motomura T (1981) Peripheral neuropathy in children on long-term phenytoin therapy. Brain and Development 3(4):375–383
Shorvon SD, Reynolds EH (1982) Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry 45(7):620–626
Black JA, Liu S, Hains BC, Saab CY, Waxman SG (2006) Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 129(Pt 12):3196–3208
Bechtold DA, Smith KJ (2005) Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 233(1–2):27–35
Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, Waxman SG (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49(2):220–229
Meienberg O, Bajc O (1975) Acute polyneuropathy caused by diphenylhydantoin intoxication (author’s transl). Dtsch Med Wochenschr 100(29):1532–1534
Dobkin BH (1977) Reversible subacute peripheral neuropathy induced by phenytoin. Arch Neurol 34(3):189–190
Ramirez JA, Mendell JR, Warmolts JR, Griggs RC (1986) Phenytoin neuropathy: structural changes in the sural nerve. Ann Neurol 19(2):162–167
Bono A, Beghi E, Bogliun G, Cavaletti G, Curto N, Marzorati L, Frattola L (1993) Antiepileptic drugs and peripheral nerve function: a multicenter screening investigation of 141 patients with chronic treatment. Collaborative group for the study of epilepsy. Epilepsia 34(2):323–331
Yoshikawa H, Abe T, Oda Y (1999) Extremely acute phenytoin-induced peripheral neuropathy. Epilepsia 40(4):528–529
Toth C (2004) Kotecha SA prolonged and excessive phenytoin therapy leading to a severe and partially reversible polyneuropathy. J Peripher Nerv Syst 9(4):198–199
Mahon AM (2016) Lacking the ‘protective label’ of diabetes: phenytoin-induced distal symmetrical peripheral neuropathy. A clinical case report. J Tissue Viability 24(16):30042–30040
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors are patent holders of two patents:
1. Topical phenytoin for use in the treatment of peripheral neuropathic pain.
2. Topical pharmaceutical composition containing phenytoin and a co-analgesic for the treatment of chronic pain.
Rights and permissions
About this article
Cite this article
Keppel Hesselink, J.M., Kopsky, D.J. Phenytoin: neuroprotection or neurotoxicity?. Neurol Sci 38, 1137–1141 (2017). https://doi.org/10.1007/s10072-017-2993-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-017-2993-7